Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?
AbstractMinimal residual disease evaluation refers to a series of molecular and immunophenotypical techniques aimed at detecting submicroscopic disease after therapy. As such, its application in acute myeloid leukemia has greatly increased our ability to quantify treatment response, and to determine the chemosensitivity of the disease, as the final product of the drug schedule, dose intensity, biodistribution, and the pharmakogenetic profile of the patient. There is now consistent evidence for the prognostic power of minimal residual disease evaluation in acute myeloid leukemia, which is complementary to the baseline prognostic assessment of the disease. The focus for its use is therefore shifting to individualize treatment based on a deeper evaluation of chemosensitivity and residual tumor burden. In this review, we will summarize the results of the major clinical studies evaluating minimal residual disease in acute myeloid leukemia in adults in recent years and address the technical and practical issues still hampering the spread of these techniques outside controlled clinical trials. We will also briefly speculate on future developments and offer our point of view, and a word of caution, on the present use of minimal residual disease measurements in “real-life” practice. Still, as final standardization and diffusion of the methods are sorted out, we believe that minimal residual disease will soon become the new standard for evaluating response in the treatment of acute myeloid leukemia. View Full-Text
Share & Cite This Article
Mosna, F.; Capelli, D.; Gottardi, M. Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress? J. Clin. Med. 2017, 6, 57.
Mosna F, Capelli D, Gottardi M. Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress? Journal of Clinical Medicine. 2017; 6(6):57.Chicago/Turabian Style
Mosna, Federico; Capelli, Debora; Gottardi, Michele. 2017. "Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?" J. Clin. Med. 6, no. 6: 57.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.